Karuna Therapeutics (KRTX +0.5%) has agreed to partner with privately held PGI Drug Discovery LLC (PsychoGenics) to identify novel candidates for severe neuropsychiatric disorders.
Under the terms of the deal, Karuna will pay PsychoGenics an undisclosed upfront amount for access to its proprietary screening platforms that leverage computer vision and machine learning. Each party is eligible for milestone payments and royalties on net sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.